STOCK TITAN

MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MBX Biosciences director Steven Ryder received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and were awarded at no cost as a compensation grant.

The award vests in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, as long as Ryder continues serving as a non-employee director. After this grant, he holds options for 12,500 underlying shares, which expire on June 4, 2036.

Positive

  • None.

Negative

  • None.
Insider Ryder Steven
Role null
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 12,500 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 12,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 12,500 options Stock option grant to director Steven Ryder
Exercise price $30.91 per share Strike price of stock options
Expiration date June 4, 2036 Option expiration
Shares underlying options 12,500 shares Common stock underlying granted options
Cost of grant $0.00 Award granted at no upfront cost to director
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 30.9100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-04T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
non-employee director financial
"subject to the non-employee director's continued services to the Company"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ryder Steven

(Last)(First)(Middle)
C/O MBX BIOSCIENCES, INC.
11711 N. MERIDIAN STREET, SUITE 300

(Street)
CARMEL INDIANA 46032

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MBX Biosciences, Inc. [ MBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$30.9106/04/2026A12,500 (1)06/04/2036Common Stock12,500$012,500D
Explanation of Responses:
1. The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
/s/ P. Kent Hawryluk, attorney-in-fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MBX director Steven Ryder report in this Form 4?

Steven Ryder reported receiving a grant of stock options for 12,500 shares of MBX Biosciences common stock. These options were awarded as compensation, with an exercise price of $30.91 per share and no cash paid upfront for the grant itself.

What is the exercise price of Steven Ryder’s MBX stock options?

The stock options granted to Steven Ryder have an exercise price of $30.91 per share. This is the fixed price he would pay per share to convert the options into common stock before their stated expiration date in June 2036.

When do Steven Ryder’s MBX stock options vest?

Ryder’s options vest in full on the earlier of one year from the grant date or the next MBX annual stockholder meeting. Vesting is conditioned on his continued service as a non-employee director through that applicable vesting date.

How many MBX shares underlie Steven Ryder’s new stock options?

The new stock option award covers 12,500 shares of MBX Biosciences common stock. Following this grant, the filing shows Ryder holding options corresponding to 12,500 underlying shares, reflecting this single compensation-related derivative position.

When do Steven Ryder’s MBX stock options expire?

The stock options granted to Steven Ryder expire on June 4, 2036. He may exercise them at $30.91 per share any time after vesting and before that expiration date, subject to the terms of the company’s equity plan and award agreement.